Company Profile
BridgeBio Stock Price, News & Catalysts
- Ticker:
- BBIO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
74.27 USD (-4.65%)
Close
Last updated: November 5, 2026
12.5B USD
Market cap
Why the stock is moving
As of Nov 5, 2026, BBIO closed down 4.65% at $74.27. No new same-company headline was identified in the current news window.
Company overview
Genetically Defined Diseases
BridgeBio Pharma develops medicines for genetic diseases and genetically driven cancers. Its decentralized portfolio model creates focused teams around individual disease programs.
Attruby
Attruby, or acoramidis, is an oral transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy. It anchors BridgeBio's commercial rare-cardiovascular franchise.
BBP-418
BBP-418 is an oral substrate-supplementation therapy under FDA review for limb-girdle muscular dystrophy type 2I/R9.
Encaleret
Encaleret is an oral calcium-sensing-receptor antagonist being prepared for regulatory submission in autosomal dominant hypocalcemia type 1.
Infigratinib
Low-dose oral infigratinib targets FGFR3 signaling in achondroplasia and is advancing toward an NDA based on late-stage clinical development.
Future catalysts
- FDA action on the BBP-418 application for LGMD2I/R9 on November 27, 2026.
- FDA action on oral infigratinib for achondroplasia on February 4, 2027.
- FDA action on encaleret for autosomal dominant hypocalcemia type 1 on May 8, 2027.
- Potential European approval of encaleret for autosomal dominant hypocalcemia type 1 in the second half of 2027.
- IND submission for the BBP-717 ATTR-CM amyloid depleter in 2027.
- Topline results from the Phase 3 RECLAIM-HP study of encaleret in chronic hypoparathyroidism in early 2028.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of BridgeBio (BBIO)?
BridgeBio (BBIO) most recently closed at 74.27 USD, a -4.65% move versus the previous session.
What is the market cap of BridgeBio (BBIO)?
BridgeBio currently has a market capitalization of 12.5B USD on BioPharmSignal.
What does BridgeBio do?
Genetically Defined Diseases BridgeBio Pharma develops medicines for genetic diseases and genetically driven cancers. Its decentralized portfolio model creates focused teams around individual disease programs. Attruby Attruby, or acoramidis, is an oral transthyretin stabilizer approved for transthyretin amyloid cardiomyopathy. It anchors BridgeBio's...
On which exchange is BBIO stock listed?
BridgeBio (BBIO) is associated with NASDAQ, United States, Biopharma.
What is BBP-418?
FDA action on the BBP-418 application for LGMD2I/R9 on November 27, 2026.
Which conditions is BridgeBio targeting with BBP-418?
BridgeBio is associated with cancer therapeutics, cardiovascular disease, genetic disease based on its company overview and current catalyst commentary.
How does BridgeBio describe recent progress with BBP-418?
FDA action on the BBP-418 application for LGMD2I/R9 on November 27, 2026.
What is BBP-717?
IND submission for the BBP-717 ATTR-CM amyloid depleter in 2027.